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ABSTRACT The intrinsic immunity factor CD317 (BST-2/HM1.24/tetherin) imposes a barrier to HIV-1 release at the cell surface
thatcanbeovercomebytheviralproteinVpu.ExpressionofVpuresultsinareductionofCD317surfacelevels;however,the
mechanismofthisVpuactivityanditscontributiontothevirologicalantagonismareincompletelyunderstood.Here,wechar-
acterizedtheinﬂuenceofVpuonmajorCD317trafﬁckingpathwaysusingquantitativeantibody-basedendocytosisandrecy-
cling assays as well as a microinjection/microscopy-based kinetic de novo expression approach. We report that HIV-1 Vpu in-
hibitedboththeanterogradetransportofnewlysynthesizedCD317andtherecyclingofCD317tothecellsurface,whilethe
kineticsofCD317endocytosisremainedunaffected.VputrappedtrafﬁckingCD317moleculesatthe trans-Golginetwork,where
thetwomoleculescolocalized.ThesubversionofbothCD317transportpathwayswasdependentonthehighlyconserveddiser-
ineS52/S56motifofVpu;however,itdidnotrequirerecruitmentofthediserinemotifinteractorandsubstrateadaptorofthe
SCF-E3ubiquitinligasecomplex, -TrCP.TreatmentofcellswiththemalariadrugprimaquineresultedinaCD317trafﬁcking
defectthatmirroredthatinducedbyVpu.Importantly,primaquinecouldfunctionallyreplaceVpuasaCD317antagonistand
rescueHIV-1particlerelease.
IMPORTANCE HIV efﬁciently replicates in the human host and induces the life-threatening immunodeﬁciency AIDS. Mamma-
liangenomesencodeproteinssuchasCD317thatcaninhibitviralreplicationatthecellularlevel.Asacountermeasure,HIVhas
evolvedgeneslikevputhatcanantagonizetheseintrinsicimmunityfactors.InvestigatingthemechanismbywhichVpuover-
comesthevirionreleaserestrictionimposedbyCD317,weﬁndthatVpusubvertsrecyclingandanterogradetrafﬁckingpath-
waysofCD317,resultinginsurfacelevelsoftherestrictionfactorinsufﬁcienttoblockHIV-1spread.Thisdescribesanovel
mechanismofimmuneevasionbyHIV.
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A
s obligate intracellular parasites, viruses rely for their replica-
tion on a wide array of host cell machineries. This intimate
relationship is also exploited by the host, which has developed, in
addition to adaptive immune responses, innate and intrinsic im-
mune mechanisms to fend off viral intruders. In the case of HIV,
the proteins TRIM5 and CD317 (BST-2/HM1.24/tetherin), as
well as members of the APOBEC family of cytidine deaminases,
areprominentexamplesofhostcellfactorsthatcanrestrictHIV-1
replication at distinct steps of the viral life cycle. General mecha-
nisms of virus-host coevolution and the high genetic plasticity of
theHIV-1genomehaveledtotheemergenceofvirusvariantsthat
are insensitive to such restrictions. For example, the capsid pro-
tein of HIV-1 cannot be efﬁciently recognized by the human or-
tholog of TRIM5 (1). As an additional strategy, HIV-1 has
evolved accessory genes that are not essential for virus replication
per se, the expression of which, however, allows the virus to over-
come speciﬁc restriction factors. The Vif and Vpu proteins, viral
antagonists that counteract human APOBEC and CD317 pro-
teins, respectively, thus constitute important genetic adaptations
of HIV-1 that facilitate virus replication in the face of an active
intrinsic immunity (2).
CD317 is a glycosylated type II transmembrane protein with an
unusual topology: it has a short cytoplasmic N terminus, a single
membrane-spanning domain, and a large extracellular domain that
contains a coiled-coil and that is tethered to cholesterol-rich mem-
brane microdomains by virtue of its glycophosphatidylinositol an-
chor at the C terminus (3–6). Cell surface CD317 is endocytosed
by an AP-2- and clathrin-dependent pathway (7, 8). The fate of
internalizedCD317moleculeshasnotbeenstudiedindetail;how-
ever, it is likely to include a yet-to-be-deﬁned recycling pathway.
In the context of viral infection, CD317 was identiﬁed as a
potent, type I interferon-induced restriction factor of HIV-1 par-
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producing cells (hence the name “tetherin”) (9). This activity re-
quiresmultimerizationofCD317,andthecurrentmodelsuggests
that dimers of the restriction factor physically bridge the cell’s
plasma membrane and nascent virions or bridge virions among
each other (5, 9, 10). In addition to preventing the release of viri-
onsintotheextracellularspace,CD317mayalsoaffectthedissem-
ination of HIV-1 particles by the cell-to-cell route (11, 12), al-
though this is still a matter of controversy (13). The antiviral
spectrum of CD317 is not restricted to HIV and includes nonhu-
man primate lentiviruses, simple retroviruses, ﬁloviruses, arena-
viruses, rhabdoviruses, inﬂuenza virus, and herpesviruses (9, 14–
20).
Many of these unrelated viruses encode viral antagonists to
overcome the particle release barrier imposed by CD317. In the
case of HIV-1, this function is exerted by the accessory protein
Vpu. Vpu is a ~16-kDa transmembrane protein that is best stud-
ied for its ability to degrade the HIV-1 entry receptor CD4 early
during biosynthetic transport (21, 22). Via the substrate recogni-
tion unit beta-transducin repeat-containing protein (-TrCP),
Vpu recruits the multisubunit SCF (Skp1/cullin/F-box
protein)-E3 ubiquitin ligase complex to the endoplasmic reticu-
lum(ER)andbridgesittonewlysynthesizedCD4molecules(23).
As a consequence, CD4 molecules are retained in the ER followed
by targeting to the ER-associated degradation (ERAD) pathway
(22,24).TheVpu–-TrCPinteractionrequiresacanonicaldiser-
ine DSGxxS (S52/S56) motif in the cytoplasmic tail of Vpu (23,
25).
The mechanism by which Vpu counteracts CD317 is far less
well understood. The diserine motif of Vpu is also involved in
antagonism of CD317 (26, 27), and cellular levels of CD317 were
frequently found to be decreased in the presence of Vpu (26–29).
This led to the hypothesis that, in analogy to its action on CD4,
Vpu may counteract CD317 by triggering its degradation. How-
ever, the extent of depletion of CD317 cellular pools does not
strictly correlate with CD317’s ability to rescue HIV-1 particle
release (30–32), and a CD317 mutant that is resistant to Vpu-
mediated depletion can still be efﬁciently antagonized (33). Fur-
thermore, the cell surface density of the restriction factor was
foundtobereducedinthepresenceofVpuandinpartuncoupled
from alterations of levels of intracellular CD317 pools (26, 30, 33,
34).Conceivably,thereductionofCD317’ssurfacelevelsandthus
of the levels at sites of virus budding may be sufﬁcient to account
forVpu’santagonisticvirologicalproperties,andsofaraninverse
relationship between Vpu’s effects on CD317 surface exposure
and virus production has been noted (26, 30, 33–35). Direct ex-
perimental evidence for a cardinal role of CD317 downregulation
in Vpu’s antagonistic property is, however, lacking. Moreover, by
which mechanism Vpu deregulates the CD317 surface density is
unclear. Even though a physical interaction between Vpu and
CD317 and a colocalization of the two proteins at intracellular
membranes within or near the trans-Golgi network (TGN) has
been reported (30, 36, 37), the speciﬁc transport pathway(s) of
CD317 affected by Vpu is undeﬁned. A slightly enhanced inter-
nalizationrateofCD317(38,39)oradecreasedoutwardtransport
of CD317 (30, 37) has recently been suggested, with considerable
controversyremaining(40,41).Inthepresentstudy,wetherefore
soughttodeﬁnethemechanismbywhichVpualterstrafﬁckingof
CD317 to induce a reduction of the cell surface density of the
restriction factor and to analyze whether these alterations in in-
tracellularCD317transportarecriticalforVpu’sroleasanantag-
onist of the CD317-imposed HIV-1 release restriction.
RESULTS
HIV-1 Vpu does not affect the internalization rate of CD317. A
selective downregulation of cell surface CD317 can be accom-
plished by three possible mechanisms: (i) an enhanced rate of
endocytosisofcellsurfaceCD317molecules,(ii)areducedrateof
recycling of previously internalized CD317 molecules back to the
cellsurface,or(iii)adiminishedrateofresupplyofnewlysynthe-
sizedCD317fromwithinthecell.Wethereforesetouttoconduct
a comprehensive characterization of Vpu’s effect on CD317 traf-
ﬁckinginHeLa-derivedTZM-blcells,whichexpresshighlevelsof
endogenous CD317 (42).
Internalization of CD317 from the cell surface occurs by a
clathrin-dependent pathway (7, 8). Conﬂicting studies reported
either an enhancing effect (38, 39) or no effect (30, 31, 43) of Vpu
onCD317internalization.Inthepresentstudy,TZM-blcellswere
transfected with expression plasmids encoding Vpu.GFP or GFP
(green ﬂuorescent protein) alone and analyzed 1 day later by ﬂow
cytometry.Atsteadystate,expressionofVpu.GFPreducedsurface
levels of CD317 to ~35% of those observed in GFP-expressing
control cells (see Fig. S1B in the supplemental material). These
transfectedcellswereusedinakineticantibody(Ab)-basedendo-
cytosis assay to determine CD317 internalization kinetics (see
schematic in Fig. S1A). First, cells were incubated at 4°C with
saturating concentrations of the unconjugated anti-HM1.24/
CD317monoclonalantibody(MAb)thatrecognizesanepitopein
the extracellular domain of CD317 (44). Subsequently, cells were
shiftedto37°Cforvarioustimeperiods(t0to40min),allowing
endocytosis of CD317 to occur. Finally, cells were stained with a
ﬂuorescently labeled secondary antibody at 4°C to detect the re-
maining antibody-CD317 complexes at the cell surface by ﬂow
cytometry. Employing this protocol, CD317 was internalized at a
rate of ~2% per min in GFP-expressing control cells during the
ﬁrst 20 min with a loss of ~50% of the surface pool of CD317 by
40min(Fig.S1C,ﬁlledcircles),consistentwithdynamicsreported
inrecentstudies(30,31,43).Importantly,expressionofVpu.GFP
signiﬁcantly affected neither the rate nor the kinetics of CD317
internalization (Fig. S1C, open circles). Comparable results were
obtained in TZM-bl cells expressing untagged Vpu together with
GFPorwhenanalternativeanti-CD317antibody(polyclonalrab-
bit BST-2 antiserum [32]) was used (data not shown). Thus, in
agreement with several recent reports (30, 31, 43), Vpu does not
signiﬁcantly alter the endocytosis rate or kinetics of endogenous
CD317 in TZM-bl cells.
EstablishmentandvalidationofaCD317recyclingassay.To
determine if Vpu affects the trafﬁcking of endocytosed CD317
molecules back to the cell surface, we developed an antibody-
based recycling assay (see schematic in Fig. 1A). This assay, in
contrasttopreviouslyreportedapproaches(45–48),doesnotrely
on harsh protease treatment, acid stripping, radioactive or biotin
labeling, or ligand-induced endocytosis. Instead, it kinetically de-
tects CD317 molecules surfacing at the plasma membrane in
transfected or infected cells from intracellular pools, into which
they had recently been endocytosed. In detail, TZM-bl cells were
ﬁrst incubated at 4°C with saturating concentrations of the un-
conjugated anti-HM1.24/CD317 MAb. Subsequently, a tempera-
ture shift to 37°C for various time periods (t  0 to 12 min)
allowed,besidesendocytosisofantibody-CD317complexes,recy-
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the cell surface (Fig. 1A, blue CD317 molecules). These newly
surface-exposed molecules were then directly detected using the
identical anti-HM1.24/CD317 MAb, which had been covalently
coupled to the allophycocyanin (APC) ﬂuorophore. It is impor-
tanttorealizethatmoleculesremainingatthecellsurfacethatstill
carry the unlabeled MAb cannot be recognized by the identical
MAb coupled to APC.
As depicted in the ﬂuorescence-activated cell sorting (FACS)
dot plots in Fig. 1B, saturation of pGFP-transfected cells’ CD317
surface population with the unconjugated anti-HM1.24/CD317
MAb was efﬁcient, demonstrated by the low background staining
with the APC-conjugated MAb (Fig. 1B, middle panel; t  0 min;
mean ﬂuorescence intensity [MFI], 15) compared to that of un-
treated cells at steady state (Fig. 1B, left panel; MFI, 314). Within
12 min of incubation at 37°C, a prominent population of previ-
ouslyunlabeledCD317moleculesappearedatthecellsurfacethat
could be detected by the APC-conjugated anti-HM1.24/CD317
MAb (Fig. 1B, right panel; t  12 min; MFI, 113).
To evaluate whether shedding of the unconjugated, surface-
bound anti-HM1.24/CD317 MAb contributes to the increasing
binding of the APC-conjugated antibody in this recycling assay,
FIG 1 CD317 recycling is rapid and sensitive to pri-
maquine. (A) Schematic representation of an
antibody-based recycling assay. For assay validation,
TZM-bl cells were transfected with a GFP-expressing
plasmid. Twenty-four hours posttransfection, cells’
CD317 surface pool was ﬁrst labeled with saturating
concentrationsofunconjugatedanti-HM1.24/CD317
MAb at 4°C before incubation at 37°C for the indi-
cated time intervals (t  0 to 12 min) to allow recy-
cling of previously intracellular, unlabeled CD317
molecules (blue). Subsequently, cells were stained
with the identical anti-HM1.24/CD317 MAb, cova-
lentlyconjugatedtoAPC,at4°C,andtheMFIofGFP-
positive cells was quantiﬁed by ﬂow cytometry. Vesi-
cles with recently internalized cargo are shown in
magenta; recycling vesicles are shown in gray. (B)
Representative FACS dot plots of CD317-APC stain-
ingoftransfectedTZM-blcellsintherecyclingassayat
steadystate(left),att0min(middle),andatt12
min (right). The red gate depicts the high-GFP-
expressing cells, and the respective MFI values are in-
dicated within the gate. (C and D) Anti-HM1.24/
CD317 MAb is not shed from antibody-CD317
complexes. (C) TZM-bl cells were ﬁrst stained with
unconjugated anti-HM1.24/CD317 MAb at 4°C,
washed, and incubated for either 0 min or 40 min on
ice. Antibody-CD317 complexes at the cell surface
were subsequently detected with an APC-conjugated
secondary antibody at 4°C and quantiﬁed by ﬂow cy-
tometry. (D) TZM-bl cells were transfected with ex-
pression plasmids encoding either GFP (ﬁlled circles)
or the dominant negative dynamin K44A.GFP mu-
tant (open circles). Twenty-four hours posttransfec-
tion, cells were analyzed in the endocytosis assay as
described for Fig. S1A and C. The graph depicts the
kinetics of relative CD317 levels remaining at the sur-
face of viable, GFP-positive, or dynamin K44A.GFP-
positive cells as relative percentages of the respective
MFIsatt0min,whichweresetto100%.Shownare
the arithmetic means  standard deviations of tripli-
cates from one experiment. Two independent assays
were performed. (E) Recycling assay validation.
pGFP-transfected TZM-bl cells were pretreated with
either brefeldin A (0.2 mM, 2 h), cycloheximide
(0.2 mM, 2 h), or primaquine (0.5 mM, 45 min) or
were left untreated and subsequently analyzed in the
CD317 recycling assay. The graph depicts the relative
cellsurfaceexpressionofCD317detectedbytheAPC-
conjugated anti-HM1.24/CD317 MAb and is pre-
sented as the factor of enhancement of the MFIs at
differenttimepointsrelativetotheMFIatt0,which
was set to 1. Shown are the arithmetic means stan-
dard deviations of triplicates of one out of three inde-
pendent experiments. (F) Microphotographs of
brefeldinA-treated(0.2mM,2h)anduntreatedcon-
trol cells stained for the Golgi apparatus marker
-COP (red). Nuclei were counterstained with
Hoechst stain. Scale bars, 10 m.
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labeled cells for 40 min at 4°C, at which temperature receptor
endocytosis does not occur, did not result in a reduction of anti-
bodylevels,assessedwithanAPC-conjugatedsecondaryantibody
(Fig. 1C). Second, blocking CD317 endocytosis by expression of
the dominant negative dynamin K44A.GFP mutant (49) resulted
in stable levels of the unconjugated surface-bound anti-HM1.24/
CD317 MAb for prolonged periods even at 37°C (Fig. 1D, open
circles). Together, these ﬁndings demonstrate that signiﬁcant an-
tibody shedding does not occur and is therefore not a confound-
ing issue in this recycling assay.
Employing this assay, the appearance of previously intracellu-
lar CD317 at the surface of untreated TZM-bl control cells was
detected at a rate of ~3% per min, resulting in a more than 4-fold
increase of CD317 surface levels within 12 min (Fig. 1E, black
circles). To discriminate between newly surface-exposed CD317
glycoproteinsthatoriginatedeitherfromrecyclingcompartments
or from the biosynthetic pathway, we inhibited the anterograde
transport through the Golgi apparatus by pretreatment of cells
withbrefeldinA.DespiteefﬁcientdisruptionoftheGolgiappara-
tus (see dispersed -COP staining in the presence of brefeldin A,
Fig. 1F), the rate of CD317 molecules surfacing at the plasma
membrane was not diminished (Fig. 1E, black triangles). Simi-
larly, shutdown of de novo protein biosynthesis by cycloheximide
pretreatment of cells did not affect results of the recycling assay
(Fig. 1E, open triangles). CD317 proteins in the anterograde bio-
syntheticpathway,therefore,donotsigniﬁcantlycontributetothe
surfacing of CD317 molecules within the 12-min observation pe-
riod. In sharp contrast, virtually no additional CD317 molecules
surfaced in cells treated with primaquine (PQ), a lysosomotropic
aminethathasastronginhibitoryeffectontherecyclingofcertain
receptors (50–52), including major histocompatibility complex
(MHC) class II glycoproteins and the transferrin receptor. We
conclude that our antibody-based assay speciﬁcally and quantita-
tively detects recycling of previously endocytosed CD317 mole-
culesfromintracellularcompartmentsbacktothecellsurface.We
ﬁndthatCD317exhibitsafastrecyclingkineticthatissensitiveto
treatment with PQ.
Vpu diminishes CD317 recycling. Next we employed this as-
saytodeterminewhetherHIV-1VpuaffectsthekineticofCD317
recycling. Parallel analysis of CD4, the major binding receptor of
HIV-1, was included as an informative reference since this recep-
toristargetedbyVpuexclusivelyinthebiosyntheticpathway(21,
22). Transient expression of Vpu.GFP reduced surface levels of
both CD317 and CD4 on TZM-bl cells at steady state to similar
degrees, by 64 and 54%, respectively, compared to GFP-
expressingcontrolcells(Fig.2A).CellswhichexpressedVpu.GFP
showedamarkedlyreducedkineticofCD317recyclingcompared
tothatofGFP-onlycontrols(P0.018,Fig.2B;seealsoFig.S2for
data from an independent experiment including primary FACS
plots). At 12 min, recycled molecules amounted to an increase of
only 3.1-fold (Vpu.GFP) compared to 6.2-fold (GFP) relative to
levels at t  0 min (Fig. 2B). Comparable results were obtained
uponexpressionofuntaggedVputogetherwithGFP(Fig.2C).In
contrast, the recycling of CD4 was not inhibited, but rather mod-
estly accelerated, by Vpu.GFP (Fig. 2D), although the reductions
ofsteady-statesurfacelevelsofthetworeceptorswerecomparable
(Fig.2A).Theseresultsunderscoredthespeciﬁcityoftheassayfor
the detection of receptors that are recycling from intracellular
compartments, and not those in the biosynthetic anterograde
FIG 2 HIV-1 Vpu interferes with the recycling of CD317, but not of CD4.
TZM-blcellsweretransfectedwithexpressionplasmidsencodingVpu.GFPor
GFP or cotransfected with expression plasmids for untagged Vpu and GFP
(Vpu  GFP). Twenty-four hours posttransfection, cells were stained for sur-
facesteady-statelevelsofeitherCD317orCD4andanalyzedbyﬂowcytometry
(A),usedinaCD317recyclingassayasdescribedinthelegendtoFig.1(Band
C), or used in a recycling assay for CD4, which was performed analogously to
that for CD317 (D). Shown are arithmetic means  standard deviations of
triplicates.SevensimilarassayswereperformedforpanelB,twosimilarassays
were performed for panel C, and four similar assays were performed for panel
D.
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as a trafﬁcking step inhibited by HIV-1 Vpu.
ToconﬁrmtheimpactofVpuonCD317recyclinginaninfec-
tion context, TZM-bl cells were challenged with vesicular stoma-
titis virus G protein (VSV-G)-pseudotyped GFP reporter viruses
based on the NL4-3 strain of HIV-1 (53). An internal ribosome
entry site (IRES) inserted downstream of the nef gene preserves
expression of all viral genes and supports long terminal repeat
(LTR)-driven GFP expression in infected cells. TZM-bl cells in-
fected with the Vpu-deﬁcient HIV-1 IRES.GFP virus (HIV-1
vpuIRES.GFP,Fig.3A,blackcircles)displayedCD317recycling
rates that were comparable to those seen in GFP-expressing con-
trol cells (compare with Fig. 2B and C). In contrast, recycling of
CD317 was impaired in cells infected with the HIV-1 wild-type
(wt) IRES.GFP virus compared to those infected with the HIV-1
vpu IRES.GFP virus (P  0.023, Fig. 3A, open circles). While
being statistically signiﬁcant, the impact of Vpu expressed from
this reporter virus on CD317 recycling in infected TZM-bl cells
was slightly less pronounced than that seen for ectopic expression
of Vpu or Vpu.GFP. These HIV-1-infected TZM-bl cultures dis-
played the expected Vpu-dependent virological phenotypes: the
wtviruswasreleasedmoreefﬁcientlythanitsVpu-negativecoun-
terpart (Fig. 3C and 3D) and mediated a reduction of steady-state
surface levels of CD317 (Fig. 3B). Furthermore, recycling of en-
dogenousCD317wasalsofoundtobeseverelyimpairedinaVpu-
dependent manner in HIV-1-infected Jurkat T cells (Fig. S3). To-
gether, these results demonstrate that Vpu exerts a profound and
target molecule-speciﬁc inhibitory effect on the recycling of
CD317.
Vpu blocks anterograde transport of CD317 to the cell sur-
face. We next asked whether Vpu, in addition to its inhibitory
effect on CD317 recycling, can also affect the transport of newly
synthesizedCD317moleculestothecellsurface.Sincethespeciﬁc
analysis of biosynthetic transport is technically challenging, we
employedamicroscopy-basedkineticdenovoexpressionanalysis:
plasmids encoding CD317, which carries an HA tag embedded in
the extracellular domain (CD317-HAint) (35), and pVpu.GFP (or
pGFP) were comicroinjected into the nuclei of TZM-bl cells and
the localization of newly expressed proteins was analyzed in cells
ﬁxed at different time points postinjection.
Protein expression was readily detectable 1 h postinjection by
confocal microscopy. At this early time point, CD317-HAint mol-
ecules showed a primarily perinuclear, ER-like distribution in
GFP-coexpressing control cells, while CD317-HAint localization
at the plasma membrane was still rarely observed (Fig. 4A; quan-
tiﬁcation is shown in Fig. 4E). Already at 2 h, newly synthesized
CD317-HAintmoleculesweredetectableatthesurfaceof~50%of
cells, indicative of a rapid transport to the plasma membrane. By
16 h, a strong surface localization was apparent in over 90% of
cells in addition to cytoplasmic pools of the restriction factor
(Fig. 4C and 4E).
Coexpression of Vpu.GFP, however, had a pronounced effect
on the subcellular distribution of newly synthesized CD317-
HAint: already at 1 h postinjection CD317 localized to a compact
perinuclearcompartment(Fig.4B)morphologicallydistinctfrom
that observed in the GFP-expressing control cells (Fig. 4A) and
consistent with a TGN-like pattern (Fig. 4J) already at this early
time point. This predominant perinuclear localization of newly
synthesized CD317-HAint frequently persisted in a somewhat
more dispersed pattern even at the latest time point (16 h,
FIG 3 HIV-1-infected cells display a Vpu-dependent recycling block for
CD317.TZM-blcellswereinfectedwitheitherVSV-G-pseudotypedHIV-1wt
IRES.GFP or HIV-1 vpu IRES.GFP. (A) Twenty-four hours postinfection,
GFP-positive,productivelyinfectedcellswereanalyzedintheCD317recycling
assay. (B) Forty-eight hours postinfection, relative CD317 surface levels were
analyzed on GFP-positive cells with MFI values for HIV-1 vpu IRES.GFP-
infected cells set to 100%. Shown are arithmetic means  standard errors of
themeansofthreeindependentexperiments.(C)Forty-eighthourspostinfec-
tion, supernatants of wt and vpu virus-infected cultures were harvested and
the release of infectious particles was assessed in a standard infectivity assay.
The percentages of HIV-1-infected cells are given below the graph. (D) Cor-
responding cell lysates were analyzed by Western blotting for Vpu and Gag
proteins. Mitogen-activated protein kinase (MAPK) served as a loading con-
trol.
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plasma membrane localization of CD317-HAint (Fig. 4F). This
striking block to CD317 surface transport was seen also for un-
tagged Vpu coexpressed with GFP (Fig. S5A to S5C) and in
HT1080 cells, which express no endogenous CD317 (9) (Fig. S5D
to S5I). To test whether this defect in anterograde CD317 trans-
port can be recapitulated in primary HIV target cells, monocyte-
derived macrophages were comicroinjected with expression plas-
midsencodinganinternallyGFP-taggedCD317(3)andplasmids
for either Vpu.HcRed or the red ﬂuorescent protein control
(Fig. S6). Six hours postmicroinjection, 17 out of 21 control mac-
rophages displayed a clear surface localization of CD317.GFP
(Fig. S6A and S6C). In contrast, none of the 15 macrophages
which coexpressed Vpu.HcRed had an appreciable plasma mem-
brane expression at this time point and CD317.GFP primarily
localized in a perinuclear compartment (Fig. S6B and S6C). Also
16 h postinjection, CD317 had not reached the cell surface in
Vpu-positive macrophages (data not shown), indicating a severe
transport defect.
To determine whether the perinuclear accumulation of
CD317-HAint in Vpu.GFP-expressing cells at later time points
(Fig. 4D) reﬂected a combination of the viral proteins’ impact on
the trafﬁcking of newly synthesized molecules in the anterograde
pathway and that on recycling populations, a plasmid encoding
the dominant negative dynamin K44A mutant fused to mCherry
wascomicroinjected.CoexpressionofthisinhibitorofCD317en-
FIG 4 Vpu disrupts anterograde transport of
newly synthesized CD317 to the cell surface and
traps trafﬁcking CD317 molecules in the trans-
Golgi network. The nuclei of TZM-bl cells, grown
on coverslips, were comicroinjected with a CD317-
HAint expression plasmid together with vectors en-
coding either GFP (A and C) or Vpu.GFP (B and
D).Approximately200cellsweremicroinjectedper
plasmidcombination.Subsequently,cellswerecul-
tivatedfor1,2,6,or16handthenﬁxed,permeabil-
ized,andstainedwithananti-HAMAbfollowedby
an Alexa 568-conjugated secondary Ab (red stain-
ing) to detect newly synthesized CD317-HAint.( E
and F) By staining, cells were categorized as those
which, besides intracellular staining, also displayed
a clear plasma membrane staining (“plasma mem-
brane”) or those with an exclusive intracellular
staining(“intracellular”)ofCD317-HAintuponco-
expression of either GFP (E) or Vpu.GFP (F). His-
togram bars depict the relative percentage of cells
for each time point from at least 150 cells that were
analyzed out of three independent microinjection
experiments. (G to J) Localization studies for traf-
ﬁcking CD317 molecules. (G and H) Internalized
antibody-CD317 complexes. TZM-bl cells grown
oncoverslipsweretransfectedwithexpressionplas-
mids encoding either GFP or Vpu.GFP. Twenty-
four hours posttransfection, cells were stained with
unconjugatedanti-HM1.24/CD317MAbat4°Cbe-
fore incubation at 37°C for 180 min. Anti-HM1.24
MAb–CD317 complexes were visualized in ﬁxed
and permeabilized cells using an Alexa 660-
conjugated secondary antibody (blue staining). In
addition,cellswerestainedwithananti-TGN46Ab,
which was detected with an Alexa 568-conjugated
secondary antibody (red staining). Single-channel
and merged confocal microphotographs for the lo-
calization of GFP or Vpu.GFP (both green), anti-
HM1.24–CD317 complexes, and TGN46 are
shown. (I and J) Newly synthesized CD317.
TZM-bl cells were microinjected with plasmids en-
coding either GFP or Vpu.GFP as described above.
Subsequently,cellswerecultivatedfor1or16hand
then ﬁxed, permeabilized, and stained with an
anti-HAMAbfollowedbyanAlexa660-conjugated
secondary Ab (blue staining) and the TGN marker
TGN46 (red staining). Microphotographs shown
are representative for three independent experi-
ments.InpanelsA,B,D,H,I,andJ,cellcircumfer-
ences are indicated. Scale bars, 10 m. “Zoomed
Merge”inpanelsGandHreferstoahighermagni-
ﬁcation of the box depicted in the image above in
which the indicated color channels are superim-
posed.
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redistribution of newly synthesized CD317-HAint in Vpu.GFP-
expressing cells (data not shown). This indicates that successfully
plasma membrane-targeted and subsequently endocytosed mole-
cules do not contribute signiﬁcantly to the pronounced localiza-
tion phenotype of CD317 in this assay. These results demonstrate
the potential of Vpu to strongly inhibit the anterograde transport
of newly synthesized CD317 molecules to the plasma membrane
and to induce their accumulation in a perinuclear compartment.
Vpu traps trafﬁcking CD317 molecules in the trans-Golgi
network. We next performed a confocal microscopy study to
characterize the long-term fate of anti-HM1.24 MAb-labeled
CD317 molecules that were endocytosed from the surface of
TZM-bl cells expressing either GFP or Vpu.GFP following a tem-
perature shift from 4°C to 37°C. When we focused exclusively on
thecellsurfacepopulationofCD317-antibodycomplexesinnon-
permeabilized cells, rapid removal of CD317 was observed in the
presence of GFP and Vpu.GFP (Fig. S4A and S4C, compare 0 and
30 min). These internalized CD317-antibody complexes efﬁ-
ciently reemerged at the cell surface of GFP-expressing control
cells 6 h postinternalization (Fig. S4A, left panel, and S4C), indi-
cating that the antibody-CD317 complexes had remained intact
during internalization and recycling and that full rounds of
CD317 endocytosis and recycling likely take signiﬁcantly longer
thantheresurfacingofintracellularpoolsthatwedetectedbyﬂow
cytometry.ConﬁrmingourresultsfromtheFACS-basedrecycling
assay, Vpu.GFP potently blocked this resurfacing of CD317 mol-
ecules (Fig. S4A, right panel, and Fig. S4C). Analysis of total cel-
lular pools of CD317-antibody complexes on cells that were per-
meabilized prior to staining conﬁrmed this Vpu-mediated block
in CD317 recycling and indicated that Vpu retains CD317 pools
thatwerepreviouslyinternalizedfromthecellsurfaceinaperinu-
clear compartment (Fig. S4B).
Recent reports suggested that under steady-state conditions
Vpu colocalizes with CD317 in the TGN (30, 36, 54). To ﬁrst test
whether Vpu selectively induces an accumulation of recently en-
docytosed antibody-CD317 complexes in this membranous net-
work, we conducted colocalization studies in TZM-bl cells. In-
deed, Vpu.GFP expression resulted in a pronounced
accumulation of anti-HM1.24 MAb-CD317 complexes in or near
TGN46-positive compartments 180 min after internalization
(Fig. 4H). This extensive colocalization was not observed in un-
transfected neighboring cells or in GFP-expressing controls
(Fig.4G).Similarly,theperinuclearcompartmentinwhichnewly
synthesized CD317-HAint molecules accumulated in Vpu.GFP-
coexpressing cells following plasmid microinjection strongly co-
localized with TGN46 (Fig. 4J). Thus, both recently endocytosed
andnewlysynthesizedCD317moleculesintheanterogradetrans-
portpathwayaccumulateintheTGNuponVpucoexpression.Of
note, Vpu.GFP also displayed signiﬁcant colocalization with this
TGN-associated CD317 pool.
InhibitionofCD317recyclingandanterogradetransportde-
pends on the diserine motif in Vpu. Since the highly conserved
serineresidues52and56inthecytoplasmictailofVpuarecritical
for antagonizing the CD317-imposed restriction on HIV-1 parti-
clereleasewhenexpressedincisortrans(26,34,55,56),wetested
whether this diserine motif affects Vpu’s ability to inhibit the re-
cycling and anterograde transport of CD317. Consistent with a
numberofrecentreports(29,31,34,55,56),weobservedthatthe
reduction of CD317 steady-state surface levels in TZM-bl cells
dependedonVpu’sdiserinemotif,asalaninereplacementsofser-
ineresidues52and56(Vpu2/6)largelyabrogateditsdownmodu-
lating activity (Fig. 5A).
We then examined the recycling kinetics of endogenous
CD317 molecules in TZM-bl cells expressing either Vpu.GFP,
Vpu2/6.GFP, or GFP alone. As already shown in Fig. 2B, CD317
recycling was diminished in cells expressing Vpu.GFP compared
to that in GFP-expressing control cells (Fig. 5B). Importantly, the
recycling kinetic of CD317 in cells expressing the Vpu2/6.GFP
mutant (Fig. 5B) or the untagged Vpu2/6 together with GFP
(Fig. S7) was indistinguishable from that in corresponding GFP
control cells (Fig. 5B and Fig. S7), indicating a requirement of the
diserine motif for Vpu’s capacity to interfere with this trafﬁcking
pathway of CD317. In addition, we also tested the involvement of
the diserine motif on the block of anterograde transport of newly
synthesized CD317-HAint induced by the viral accessory protein.
Both the kinetic and magnitude of CD317-HAint anterograde
transport to the cell surface in the microscopy-based de novo ex-
pression assay were comparable in TZM-bl cells expressing the
Vpu2/6.GFP mutant (Fig. 5C, D, and E) and in cells expressing
GFP alone (Fig. 4A, C, and E). Moreover, cells expressing
Vpu2/6.GFPdidnotdisplaythepronouncedperinuclearaccumu-
lationofCD317-HAintseeninthepresenceofVpu.GFP(compare
Fig. 5C and D and Fig. 4B and D). Together, these results suggest
that serine residues 52 and 56 are essential for Vpu’s inhibitory
inﬂuence on both the recycling and anterograde transport of
CD317 molecules.
Proteasomal degradation of CD317 and the diserine motif
interactor -TrCP are not strictly required for Vpu’s ability to
block CD317 recycling. The canonical diserine motif in Vpu is
critical for its interaction with the substrate recognition adaptor
-TrCP, which is part of the SCF-E3 ubiquitin ligase complex.
This Vpu–-TrCP interaction is important for proteasomal
and/or endolysosomal degradation of CD317 (27, 29, 31, 56).
Based on the above-established importance of the diserine motif
for Vpu’s capacity to block intracellular CD317 trafﬁcking, we
exploredtheroleofCD317degradationandcellular-TrCPlevels
in this process.
To study the requirement for proteasomal degradation, recy-
cling of CD317 was ﬁrst quantiﬁed in TZM-bl cells expressing
GFP or Vpu.GFP in the presence of the proteasome inhibitor
ALLN.Undertheseexperimentalconditions,ALLNeffectivelyin-
hibited Vpu-mediated proteasomal degradation of CD4 as as-
sessed by the fully recovered receptor’s cell surface exposure
(Fig.S8A).KineticanalysisofCD317recyclingindimethylsulfox-
ide(DMSO)-treatedcellsconﬁrmedtheinhibitionofthistrafﬁck-
ing pathway in Vpu.GFP-expressing cells compared to GFP-
expressingcontrols(Fig.5F,circles).ALLNtreatmentloweredthe
basal CD317 recycling rate (Fig. 5F, compare black circles and
triangles);however,Vpu.GFPwasstillcapableofmarkedlyreduc-
ing CD317 recycling under these conditions (Fig. 5F, triangles).
To directly assess the requirement for -TrCP in Vpu’s capac-
ity to interfere with CD317 recycling, we employed RNA interfer-
ence. TZM-bl cells were transfected twice with small interfering
RNAs (siRNAs) targeting both -TrCP isoforms, -TrCP1 and
-TrCP2.Duringthesecondtransfection,expressionplasmidsfor
Vpu.GFP or GFP were added. Because antibodies for reliable de-
tectionofthese-TrCPisoformsarelacking,werecentlyvalidated
theeffectivenessandspeciﬁcityofthesesiRNAsusingcoexpressed
Myc- or Flag-tagged -TrCP1 or -TrCP2 constructs and estab-
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® mbio.asm.org 7FIG 5 Vpu’s ability to block CD317 recycling and anterograde transport depends on its diserine motif but not on proteasomal degradation of CD317 or -TrCP. (A
andB)RecyclingCD317.TZM-blcellsweretransfectedwithexpressionplasmidsencodingeitherVpu.GFP,Vpu2/6.GFP,orGFP.Twenty-fourhoursposttransfection,
GFP-expressingcellswereanalyzedforsurfacesteady-statelevelsofCD317(A)orintheCD317recyclingassay(B).Shownarearithmeticmeansstandarddeviations
oftriplicatesofonerepresentativeofthreeindependentexperiments.(C,D,andE)NewlysynthesizedCD317.TZM-blcellswerecomicroinjectedwithCD317-HAintand
Vpu2/6.GFP expression plasmids. Cells were cultivated for 1, 2, 6, or 16 h and then ﬁxed. Next, cells were permeabilized and stained with an Alexa 568-conjugated
anti-HAMAb(redstaining)todetectnewlysynthesizedCD317-HAintmolecules.Microphotographsshownarerepresentativeforthreeindependentexperiments.Scale
bars,10m.Bystaining,cellswerecategorizedasthosewhich,besidesintracellularstaining,alsodisplayedaclearplasmamembranestaining(“plasmamembrane”)or
those with an exclusive intracellular staining (“intracellular”) of CD317-HAint upon coexpression of Vpu2/6.GFP. For each time point, at least 150 cells out of three
independent microinjection experiments were counted. (F) Inhibition of proteasomal degradation by ALLN (N-acetylleucylleucylnorleucinal) does not interfere with
Vpu’sabilitytoblockCD317recycling.TZM-blcellsweretransfectedwithexpressionplasmidsencodingeitherVpu.GFPorGFP.At6hposttransfection,eitherALLN
(50M)orDMSOsolventwasaddedtotheculturemediumfor18h.Twenty-fourhoursposttransfection,Vpu.GFP/GFP-expressingcellswereanalyzedintheCD317
recycling assay or stained for CD4 surface expression (Fig. S4A). Shown is one representative of two independent experiments. (G) -TrCP is not strictly required for
Vpu’s ability to block CD317 recycling. TZM-bl cells were transfected twice with siRNAs targeting -TrCP1 and -TrCP2 (-TrCP siRNA) or control siRNA. At the
second transfection, expression plasmids encoding either Vpu.GFP or GFP were added. Three days following the ﬁrst transfection, TZM-bl cells were harvested and
analyzedintheCD317recyclingassayorstainedforCD317(Fig.S4B)orCD4(Fig.S4C)surfaceexpression.Shownisonerepresentativeexperimentoffourindependent
experiments, and arithmetic means standard deviations of triplicates are depicted. Signiﬁcance by Student’s ttest: *, P0.05; **, P0.02; ***, P0.002.
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In the current study, levels of speciﬁc -TrCP mRNAs were re-
duced by 90% compared to those in control siRNA-transfected
cells (data not shown). As an informative Vpu–-TrCP-
dependent reference for the functionality of our gene silencing
approach, Vpu.GFP completely lost its ability to degrade CD4 in
-TrCP-silencedcells(Fig.S8B).Incontrast,Vpu.GFPstillsignif-
icantly downregulated CD317 surface levels in these cells
(Fig. S8C), although the reduction of the surface pool was less
pronouncedthanthatincontrolsiRNA-treatedcells.Importantly
and consistently, -TrCP-depleted TZM-bl cells displayed a
highly signiﬁcant, albeit slightly diminished, capacity to support
Vpu’s inhibitory inﬂuence on CD317 recycling (Fig. 5G).
Taken together, Vpu interferes with CD317 trafﬁcking via a
mechanismthatcriticallydependsonitsdiserinemotif,butVpu’s
effectonCD317recyclingdoesnotstrictlyrequireproteasomal
degradation or the interaction with the -TrCP substrate rec-
ognition domain of the SCF-E3 ubiquitin ligase complex in
TZM-bl cells. This indicates that a yet-to-be identiﬁed cellular
factor may interact with the diserine motif of Vpu to alter
CD317 trafﬁcking.
PrimaquinemimicsVpu’simpactonCD317trafﬁcking.Ad-
dition of PQ at noncytotoxic concentrations to the culture me-
dium of TZM-bl cells for as little as 45 min down-modulated
steady-state surface levels of CD317 by up to 70% (Fig. 6A) and
blocked CD317 recycling (Fig. 6B and 1E). PQ, besides acting on
the recycling of surface proteins (50, 51), has been suggested to
inhibittheformationoffunctionaltransportvesiclesinvolvedalso
intheanterogradepathwayofcertainglycoproteins(57).Wethus
wondered whether PQ affects the kinetic of cell surface exposure
of newly synthesized CD317 molecules. Cultivation of TZM-bl
cells, which had been microinjected with the plasmid encoding
CD317-HAint, in the presence of PQ inhibited the appearance of
CD317attheplasmamembrane(Fig.6Cand6D),demonstrating
an interference of the drug also with anterograde trafﬁcking of
CD317. While PQ affected the recycling and anterograde sorting
steps that are also targeted by Vpu, the drug induced bulkier ag-
gregated patches of CD317-HAint than did Vpu.GFP (compare
Fig.6CandFig.4Band4D).Interestingly,PQhadnoeffectonthe
restrictionfactor’sendocytosisrates(Fig.S9A).BothPQandVpu
markedly reduced surface levels of CD4 (Fig. 2A and Fig. S9B),
albeitviadifferentmodesofaction:PQ,incontrasttoVpu,inhib-
itedtherecyclingofCD4(compareFig.S9CandFig.2D).Collec-
tively, and similarly to Vpu, PQ potently diminishes steady-state
surface levels of CD317 by interfering with both recycling and
biosynthetic transport of the cellular restriction factor.
Primaquine mimics Vpu’s antagonistic function. Based on
theaboveﬁndings,wehypothesizedthatVpu’sabilitytointerfere
withbothrecyclingandanterogradetransportofCD317couldbe
sufﬁcient(i)toaccountforthemarkedlyreducedsurfacelevelsof
the restriction factor at steady state and (ii) to overcome the
CD317-imposed virion release restriction. The comparable mag-
nitudes of CD317 downregulation by Vpu expression and that by
PQtreatmentatsteadystateandtheirsimilarpatternsofinterfer-
ence with CD317 trafﬁcking led us to explore whether this drug
could support the release of Vpu-defective HIV-1.
To test this, TZM-bl cells were ﬁrst transfected with proviral
plasmids encoding either HIV-1 wt or the isogenic Vpu-defective
counterpart, HIV-1 vpu (schematic of experimental setup in
Fig. 6E). Thirty-six hours later, cells were washed and PQ or sol-
ventwasaddedtotheculturemediumfor3h.Followingasecond
washingsteptoremovevirusessecreteduptothispoint,cellswere
cultivated for another3hi nt h epresence or absence of PQ, and
virion release during this time interval was quantiﬁed by p24CA
enzyme-linked immunosorbent assay (ELISA), in principle as re-
ported previously (26, 42).
Solvent-treated TZM-bl cells (control) showed the expected
Vpu-dependent virological phenotype: HIV-1 wt virions, but not
HIV-1 vpu virions, were efﬁciently released from transfected
cells (Fig. 6F, black bars). Importantly, the release of Vpu-
defective HIV-1 from PQ-treated cells was elevated ~4-fold and
this release efﬁciency was statistically indistinguishable from that
seenforHIV-1wt(Fig.6F).EventhoughPQisknowntoinﬂuence
different intracellular sorting processes, the release of HIV-1 wt
virions was not affected by PQ treatment (Fig. 6F), excluding un-
speciﬁc, Vpu-independent effects of the drug on HIV-1 produc-
tion. In summary, pharmacological inhibition of CD317 trafﬁck-
ing by PQ resulted in a downregulation of CD317 steady-state
levels that was comparable to that by Vpu in terms of magnitude
and the general pattern of interference with CD317 trafﬁcking.
Most critically, this effect was sufﬁcient to overcome the CD317-
imposed release restriction for Vpu-defective HIV-1.
DISCUSSION
Thisstudyaimedat(i)identifyingwhichstepofCD317trafﬁcking
isaffectedbyHIV-1Vputoinduceareductionofsteady-statecell
surface levels of the restriction factor and (ii) analyzing whether
this interference with CD317 trafﬁcking may account for the
counteraction of the CD317-imposed restriction on HIV-1 parti-
cle release. Using kinetic ﬂow cytometry- and microscopy-based
sorting approaches, we demonstrate that Vpu diminishes antero-
gradebiosynthetictransportaswellasrecyclingofCD317.Incon-
trast,theCD317internalizationrateremainedunaffectedbyVpu.
TheblocktointracellularsortingofCD317resultedintrappingof
the restriction factor at the TGN where CD317 and Vpu colocal-
ized. The interference with CD317 transport required the highly
conserved diserine motif in the cytoplasmic tail of Vpu; however,
it did not depend on proteasomal degradation of CD317 or the
presence of the E3 ubiquitin ligase substrate adaptor -TrCP.
Treatment of cells with the lysosomotropic amine PQ induced
CD317 transport defects comparable to those observed in the
presence of Vpu, and PQ could functionally replace Vpu as an
antagonist for the CD317-imposed HIV-1 release restriction. To-
gether,theseresultsrevealthatVpuemploysadualmechanismto
trap both recycling and newly synthesized pools of CD317 at in-
tracellular membranes and establish subversion of cell surface
transportasamechanismofHIV-mediatedrestrictionfactoreva-
sion.
AspartofourcomprehensivecharacterizationofVpu’spoten-
tialeffectsonCD317trafﬁcking,weﬁrstexaminedreceptorendo-
cytosis. Despite downregulation of CD317 surface levels by up to
70%, the rate of CD317 internalization was not altered in the
presenceofHIV-1Vpu,consistentwithrecentreports(30,31,43).
Theseﬁndingsdonot,however,excludealterationsintherouteof
internalization of the restriction factor from the cell surface to
intracellular compartments, as recently proposed (38).
Recent reports provided the ﬁrst indications that Vpu may
affect intracellular trafﬁcking of CD317 (30, 37, 40, 43, 58, 59);
however, the step(s) affected as well as underlying mechanisms
has remained elusive. In the current study, we employed assay
Vpu Blocks Intracellular CD317 Trafﬁcking
May/June 2011 Volume 2 Issue 3 e00036-11
® mbio.asm.org 9systems that enabled us to directly deter-
mine transport kinetics of recycling as
well as biosynthesized pools of CD317 on
their way to the plasma membrane. We
validatedanantibody-basedCD317recy-
clingassayforthekineticandquantitative
detection of molecules trafﬁcking from
intracellularpoolsbacktothecellsurface.
The exclusive detection of recycling mol-
ecules in this assay is supported by (i) in-
sensitivity to brefeldin A-induced Golgi
apparatus disruption and a
cycloheximide-induced block in transla-
tion; (ii) the lack of inﬂuence of Vpu on
recycling of CD4 in this assay, the latter
being already retained in the ER followed
by targeting to the ERAD pathway (22,
24); and (iii) the exclusion of antibody
shedding from presaturated CD317 sur-
face pools. Our ﬂow cytometric recycling
assay, in contrast to previously reported
approaches (45–48, 50, 60, 61), does not
require potentially cytotoxic and anti-
body afﬁnity-altering protease or acidic
buffertreatmentsofcellsortheinduction
of endocytosis by a speciﬁc ligand. In this
assay, Vpu had a pronounced inhibitory
effectonCD317recyclingfollowingecto-
pic expression or HIV-1 infection. This
principalﬁndingwassupportedbyresults
from a second, microscopy-based ap-
proach,inwhichalongerobservationpe-
riod allowed tracking of antibody-CD317
complexesthatﬁrstwereinternalizedand
subsequently resurfaced. Also here, Vpu
induced a block to CD317 recycling
which coincided with an accumulation of
endocytosed CD317 at or near the TGN.
To unambiguously assess the antero-
grade transport and fate of CD317 in the
biosynthetic pathway, we performed ki-
netic microscopy-based trafﬁcking stud-
ies on newly synthesized CD317 mole-
cules. Nuclear microinjection of plasmid
DNA allowed a rapid, strong, and syn-
chronizeddenovoexpressionofbothHA-
tagged CD317 and Vpu.GFP. Here, Vpu
drastically inhibited the transport of
CD317 towards the plasma membrane.
Ofnote,thekineticanalysisofsubcellular
localization of newly synthesized CD317
inVpu-coexpressingcellsprovidedahint
that Vpu may actually accelerate the ini-
tial transport steps of newly synthesized
CD317, from the ER to the TGN, before
trafﬁcking of the restriction factor comes
to a halt at the TGN. While this experi-
mentalapproachcannotbetransferredto
HIV-1-infected cells for technical and
safety reasons, this result establishes that
FIG6 Primaquine,whichmimicsVpu’spatternofinterferencewithCD317trafﬁcking,overcomesthe
CD317-imposed release restriction of Vpu-defective HIV-1. (A and B) Recycling CD317. TZM-bl cells
werecultivatedfor45mininthepresenceorabsenceofprimaquine(PQ)(0.5mM).Subsequently,cells
were stained for surface steady-state levels of CD317 (A) and analyzed in the CD317 recycling assay as
described for Fig. 1 (B). (C and D) Cells microinjected with a plasmid encoding CD317-HAint and
subsequently cultivated in either the presence or the absence of PQ (0.15 mM) for 6 h. Microphoto-
graphs of ﬁxed, permeabilized, and anti-HA-stained cells shown are representative for three indepen-
dent experiments. Scale bars, 10 m. (E) Schematic representation of the HIV-1 release assay in cells
cultivated in the presence or absence of PQ. TZM-bl cells were transfected with a proviral plasmid
encoding either HIV-1 wt or the isogenic Vpu-defective counterpart, HIV-1 vpu. Thirty-six hours
posttransfection, cells were washed and cultivated for3hi neither the presence or the absence of PQ
(0.15mM).Cellswerewashedagaintoremoveresidualvirusandcultivatedforanadditionalperiodof
3 h in the presence or absence of PQ. Subsequently, the p24CA concentration was quantiﬁed in con-
centrated culture supernatants and cell lysates using a p24CA antigen ELISA. (F) HIV-1 release was
expressed as the percentage of total p24CA (in cells and supernatant) that was secreted as virion-
associated p24CA, in principle as reported previously (26). Values are arithmetic means  standard
deviationsoftriplicatesfromonerepresentativeoutofthreeindependentexperiments.Signiﬁcanceby
Student’s t test: **, P  0.02; ***, P  0.002; n.s., not signiﬁcant.
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ofnewlysynthesizedCD317molecules.Inlinewiththisﬁnding,a
previous study proposed Vpu as a regulator of trafﬁcking along
the secretory pathway (58). Together, our results provide a direct
demonstrationthatHIV-1Vpuinterfereswithrecyclingaswellas
anterograde transport of CD317 towards the plasma membrane,
resultinginanetreductionofantivirallyactivesurfacelevelsofthe
restriction factor.
Notably, Vpu sequestered recycling and newly synthesized
CD317populationsinaperinuclearcompartmentthatfrequently
stained positive for the TGN marker TGN46 and the viral protein
itself. These effects on two distinct cellular pools of trafﬁcking
CD317 molecules could in principle result from independent ac-
tivities of Vpu. Based on several lines of evidence, however, we
favor a direct and integrative model of Vpu’s effect on CD317
trafﬁcking. First, the Vpu-like inhibition pattern of the weak base
PQonCD317trafﬁcking(blockedrecyclingandanterogradebio-
synthetic transport and unaltered endocytosis) suggests the exis-
tence of common principles that govern the two intracellular
transport routes. Second, the TGN represents the central sorting
platforminthesecretorypathwaythatisalsoindirectconnection
withretrogradetransportpathwaysfromearly,late,andrecycling
endosomes(62,63).TheTGNthuslikelyactsasatransportcheck-
point for both newly synthesized and recycling pools of CD317,
renderingitanidealcompartmentforintracellulartrappingstrat-
egies of a viral pathogen. Finally, physical association between
Vpu and CD317 via their transmembrane domains is an estab-
lished requirement for antagonism of the HIV-1 release restric-
tion (27, 30, 64–66). In light of the pronounced colocalization of
Vpu with CD317 sequestered to the TGN, one can speculate that
Vpu, by virtue of its constant localization at this membranous
network, interacts with CD317 molecules in transit to arrest their
forward transport to the cell surface irrespective of whether they
are incorporated in recycling or secretory vesicles.
On a molecular level, the results presented establish a cardinal
role for Vpu’s diserine motif for changes induced by the viral
protein to intracellular CD317 trafﬁcking, TGN trapping of
CD317, and antagonism of the HIV-1 release restriction. In the
contextofVpu-mediateddegradationofCD4,thismotifservesas
a recruitment platform for -TrCP as part of the SCF-E3 ubiqui-
tinligasecomplexthatcouplesthereceptortoaproteasomaldeg-
radation pathway (23, 25). Importantly, Vpu still interfered with
CD317 trafﬁcking in cells, in which proteasomal degradation was
inhibited or -TrCP was silenced. Moreover, we could recently
show that both degradation of CD317 (33) and -TrCP expres-
sion (56) are not strictly required for Vpu antagonism. Collec-
tively, these ﬁndings argue for a decisive role of the diserine motif
in Vpu during TGN trapping of CD317 that is different from its
-TrCP-dependent function exerted in the context of targeted
CD4 degradation. The diserine motif in Vpu’s cytoplasmic tail
represents a bona ﬁde protein interaction site in its phosphory-
lated form that is, however, not involved in the transmembrane
domain-dependent association of Vpu and CD317 (27, 30, 64–
66). Since phosphorylation of these serine residues is apparently
required for functional antagonism of CD317 by Vpu (55), we
hypothesize that the cardinal role of the Vpu diserine motif re-
ﬂects the interaction with a yet-to-be-identiﬁed host cell pro-
tein(s) distinct from -TrCP. In this scenario, the frequently ob-
served Vpu-mediated degradation of CD317 via proteasomal
and/or lysosomal pathways reported by us and many other labo-
ratories (26–29, 32, 33, 67) would likely be a secondary conse-
quenceofalteredsortingormistrafﬁckingoftherestrictionfactor.
While CD317 degradation clearly occurs in relevant cell systems,
including infected CD4 T cells (26), it does not appear to be
strictly required for Vpu’s function as a CD317 antagonist.
The identiﬁcation of a Vpu-like phenotype imprinted on
CD317 trafﬁcking by PQ allowed us to independently address the
functional consequence of this dual trafﬁcking block on CD317
steady-state surface levels and on the release of Vpu-defective
HIV-1. Remarkably, PQ was a functional phenocopy of Vpu in
promoting virus release in cells expressing high levels of endoge-
nous CD317. While PQ and Vpu are likely to affect recycling and
anterograde transport of CD317 via distinct molecular mecha-
nisms, these results demonstrate that inhibition of select CD317
plasma membrane transport pathways is sufﬁcient to markedly
reduce CD317 surface levels. Furthermore, this suggests trafﬁck-
inginterferenceasacentralmechanismemployedbyVputoover-
come the particle release restriction.
Consistent with the correlation between the reduction of
CD317 surface exposure and enhancement of HIV-1 release in-
ducedbyVpu(29,31,33,34),thissupportsthemodelthatsurface
density of CD317 is critical for physical tethering of virions at the
plasma membrane of virus-producing cells. It is noteworthy that
the (at most) 4-fold reduction of CD317 steady-state cell surface
levels induced by Vpu is not proportional in magnitude to its
abilitytopromotevirionrelease(10-to1,000-foldenhancement).
Similarly, the potent interference of Vpu with CD317 plasma
membrane transport kinetics could be expected to cause a more
severe drop in steady-state surface levels of the restriction factor.
This might suggest the existence of CD317 subpopulations with
distinct trafﬁcking characteristics and/or susceptibility to Vpu. In
this scenario, recycling as well as secretory pools of CD317 may
conceivably have a higher antiviral potential than molecules that
reside at the cell surface for extended periods of time and are not
subject to frequent internalization. This model could reconcile
Vpu’s pronounced ability to enhance virus release while only
moderately reducing overall cell surface levels of the restriction
factor. Vpu-mediated antagonism of CD317 may thus induce
quantitativeaswellasqualitativealterationsofcellsurfacepoolsof
the restriction factor. Together, our ﬁndings establish disruption
of speciﬁc intracellular transport pathways of an antiviral host
factor as an immune escape mechanism employed by HIV-1.
MATERIALS AND METHODS
Plasmids. The plasmid pcDNA-Vphu, expressing a codon-optimized,
Rev-independentHIV-1NL4-3Vpuprotein,wasfromKlausStrebel.Vphu
S52AS56A (Vpu2/6A) was generated by site-directed mutagenesis from
pcDNA-Vphu (26). Constructs encoding codon-optimized Vpu and
VpuS52/56A fused to enhanced GFP (eGFP) (Vpu.GFP and
Vpu2/6A.GFP) have been reported previously (54). The plasmid encod-
ing human CD317, which carries the HA tag sequence inserted immedi-
ately 3= of CD317 codon 154 (referred to as CD317-HAint) was provided
by Paul D. Bieniasz (35). Constructs encoding dominant negative dy-
namin fused to either GFP (dynamin K44A.GFP) or mCherry
(DynK44A.mCherry) were provided by Ari Helenius and Hans-Georg
Kräusslich, respectively. Plasmids for CD317-GFPint (3) and Vpu.HcRed
(59) were from George Banting and Paul Spearman, respectively.
CD317 and CD4 recycling assay. Recycling assays for CD317 and
CD4wereperformedinprincipleasdepictedinFig.1A.TZM-blcellswere
transfected with constructs encoding Vpu.GFP, Vpu2/6.GFP, or GFP or
were infected with VSV-G-pseudotyped HIV-1NL4-3 wt IRES.GFP or
Vpu Blocks Intracellular CD317 Trafﬁcking
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postinfection, cells were ﬁrst incubated with saturating concentrations of
the unconjugated anti-HM1.24 MAb or anti-CD4 MAb (clone RPA-T4;
BD Pharmingen) in ice-cold binding medium (Dulbecco’s modiﬁed Ea-
gle’s medium supplemented with 2% fetal bovine serum and 20 mM
HEPES,pH7.5)at4°C.Cellswerethenwashedinbindingmediumbefore
being shifted to 37°C for 0 to 12 min. Subsequently, cells were placed on
ice followed by incubation with either APC-conjugated anti-HM1.24
MAborAPC-conjugatedanti-CD4MAb(cloneRPA-T4).Forcouplingof
anti-HM1.24MAb,theAPCﬂuorophoreLightningLinkkit(InnovaBio-
sciences)wasusedaccordingtothemanufacturer’sprotocol.Recyclingof
receptorswasquantiﬁedbyﬂowcytometryanalyzingtheAPCMFI,which
reﬂects receptor molecules newly exposed on the surface of viable cells
with identical GFP intensities (red gate indicated in Fig. 1B) during the
kinetic. The APC MFIs at different time points are presented as factors of
enhancement relative to the MFI at t  0, which was set to 1.
CD317 anterograde biosynthetic transport assay. TZM-bl or
HT1080 cells or primary human macrophages, which were grown on
coverslips,weremicroinjectedintheirnucleiwithanAIS2microinjection
apparatus using pulled borosilicate glass capillaries in principle as re-
ported previously (68). Plasmids encoding CD317-HAint or CD317.GFP
and either GFP, Vpu.GFP, Vpu2/6.GFP, or Vpu.HcRed were mixed in
water at concentrations of 7 ng/l and 10 ng/l, respectively, and coin-
jected. Following microinjection, cells were cultured for 1, 2, 6, or 16 h at
37°C to allow protein expression and trafﬁcking. At the indicated time
points, cells were ﬁxed with 4% paraformaldehyde–phosphate-buffered
saline (PBS) and CD317-HAint molecules were detected using a mouse
anti-HA MAb (Santa Cruz) followed by a goat anti-mouse Alexa 568
secondary antibody (Invitrogen). Stained cells were imaged with a Zeiss
LSM 510 confocal microscope.
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